GSK is advancing mocertatug rezetecan (mo-rez), a B7-H4-directed ADC licensed from Hansoh Pharma, into five phase 3 trials across multiple cancer indications1
Phase 1b data showed a 62% overall response rate in platinum-resistant ovarian cancer patients at the highest dose (5.8 mg/kg every three weeks), and 67% in endometrial cancer patients (4.8 mg/kg)1
The phase 1b study enrolled 180 patients, with the trial population representing a difficult-to-treat population with historical five-year survival rates of only 20-30%1
Interstitial lung disease (ILD) rates were approximately 4% across both cohorts, demonstrating a manageable safety profile1
The five phase 3 trials will focus on platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, front-line HR-proficient ovarian cancer, and first- and second-line endometrial cancer1
GSK's oncology chief Hesham Abdullah described the efficacy data as 'extremely exciting' and stated GSK expects mo-rez could become a blockbuster therapy1
Sources:
1. https://www.fiercebiotech.com/biotech/gsk-ceos-scientific-courage-propels-plans-medley-phase-3-trials-adc